Episoder
-
In this episode, we sit down with Pauline Payen, Director and Global Payer Strategy Lead for UCB’s Early Portfolio. Pauline shares her pragmatic insights into navigating the complexities of global market access.
Throughout her career, Pauline hasn't been shy of new opportunities, which has led to her taking on roles in commercial and marketing to expand her experience. In this discussion, we explore why market access is her passion. A field where, as she says, "What you do, can be life-changing for people."
Pauline describes the unique mindset essential for success in market access, as well as the importance of staying open to diverse opportunities along the way. It's an inspiring discussion on aligning personal values to professional growth.The opinions shared in this episode are Pauline's own views.
-
In this episode we're joined by GSK's Head of Market Access for General Medicines, Rupert Gale.
Rupert has been in pharma for over 27 years and is still going strong! In this discussion, he shares what resilience means to him and why he feels it's an important skill for market access leaders to leverage.
Rupert shares some wonderful stories and advice that many of us can relate to and learn from. He also reveals what's keeping him passionate about access and value as he continues his career journey.
The views shared in this episode are Rupert's own opinions and not representative of the company he is working for. -
Manglende episoder?
-
Korinna Karampampa, who is Director Market Access and Pricing at CSL Behring, joins this episode to share her views on sustainable economic development.
Korinna shares what led her into market access and explains what drives her to think outside the box to build and demonstrate a product's current and future value.
The opinions shared in this episode are Korinna’s own views and not representative of the organisation she is working for. -
In this episode we're joined by our first guest from Biotech - Ning Lu, who is Associate Director, International Pricing & Market Access at Blueprint Medicines.
Ning shares her views on the complexities of market access and what makes the Biotech industry unique. She shares what inspired her to pursue a career in market access in biotechnology and why she feels it's a dynamic role and opportunity to 'connect the dots' with everything you learn.
Ning references and recommends the book "Science Business: The promise. The reality. And the future of biotech." By Gary Pisano. More information on this title is available here. https://amzn.eu/d/5nfsQVA
The opinions shared in this episode are Ning’s own views and not representative of the organisation she is working for. -
There’s no doubt that Market Access and Pricing leaders are fast becoming strategic partners in helping their wider organisations to understand the critical role of the function. In this episode, Marco Rauland from Merck KGaA joins us to explore this topic.
Marco is Vice President Global Market Access and Pricing strategy, Pricing and Analytics. With over 25 years' experience in the field, he shares his views on the importance of clear communication when engaging all stakeholders and why MA&P leaders need to take a holistic approach to understanding all corners of drug development and launch.
We also touch on the potential for AI in market access as the industry begins to explore the use cases of this latest innovation. Plus, the challenges market access leaders are facing and what strategies can help them overcome them.
The opinions shared in this episode are Marco’s own views and not representative of the organisation he is working for.
-
In this episode we're joined by Yvonne Hilsky who is Director of Market Access at Moderna. Having spent over 30 years in industry, Yvonne shares her views on what it takes to be successful in market access, including why making mistakes are an opportunity for growth.
Yvonne explores why it's important to have strong foundations and understand the 'building blocks' of market access and shares great stories from the early stages of her career, which we're sure will resonate with many of the market access community.
-
In this special episode which coincides with Disability Pride Month, we're joined by Senior Analyst Shubham Jadhav. Shubham has Becker Muscular Dystrophy (BMD) which is a form of muscular dystrophy and causes progressive muscle weakness.
Shubham is very passionate about raising awareness of rare diseases, disability, inclusivity and accessibility. He joins Keshav Nagaraja to share his story and what we can all be doing to help those with disabilities. It's an inspiring discussion which puts this very important topic in the spotlight.
More information about Disability Pride Month can be found here:
https://www.ameridisability.com/how-to-display-disability-pride/
https://en.wikipedia.org/wiki/Disability_Pride_Month
Follow Shubham on LinkedIn here:
https://www.linkedin.com/in/shubham-jadhav-ms-%E2%99%BF-he-him-6235b5149/ -
Sam is Head of Market Access Canada at Incyte Biosciences Canada and joins the podcast to discuss the evolving market access landscape in Canada. As part of his conversation with Louise, he describes the unique challenges that market access leaders in the country are facing.
Useful resources referenced in this podcast:
March 2024 - Canadian Health Policy Institute (Patented Medicines Expenditure in Canada 1990 – 2022)
https://www.canadianhealthpolicy.com/product/patented-medicines-expenditure-in-canada-1990-2022-8th-edition/
January 2024 – Conference Board of Canada (Patented Medicines Expenditure in Canada 1990–2022 8TH Edition)
https://www.conferenceboard.ca/wp-content/uploads/2022/10/access-and-time-to-patient_jan2024.pdf
Innovative Medicines Canada – Access to Medicine
https://innovativemedicines.ca/browse-by/access-to-medicine/
April 2023 – Canadian Health Policy Journal (New cancer drugs in Canada 2012 to 2021: an economic analysis of cost, benefit, availability, and public insurance coverage)
https://www.canadianhealthpolicy.com/wp-content/uploads/2022/01/SKINNER-APR-23-New-cancer-drugs-in-Canada-2012-to-2021-final-1.pdf
April 2022 – Canadian Health Policy Institute (Access to New Medicines in Canada 2016 – 2021)
https://www.canadianhealthpolicy.com/posts/access-to-new-medicines-in-canada-2016-2021-federal-provincial-public-drug-programs-and-private-sector-drug-plans/
The opinions shared in this podcast are Sam’s own views and not representative of the company he is working for.
-
In this episode we're joined by Joao Carrasco, Director, Global Market Access Team at Bayer Pharmaceuticals. With a 12+ year career spanning both HEOR and Market Access functions, Joao shares his journey and how his strong HEOR background informs his current role.
Joao also explores the key pressures and challenges market access teams are facing and his views on the trends shaping the future of market access.
The opinions shared in this episode are Joao's own views and not representative of the company he is working for. -
In this episode we look at market access through a different lens. We're joined by Becky Germino who has extensive experience in HEOR across a broad range of pharma organisations.
Becky joined Sanofi this year as HEVA, Neurology and Immunology Team Leader and explains the key priorities for HEOR teams and their role in working closely with market access to help them define and communicate patient value.
The discussion also explores the role of AI for HEOR and market access teams and what's on the horizon that leaders should prepare for.
The opinions shared in this episode are Becky's own views. -
Adrian Harrington, Senior Director Value and Access at Biogen, joins the podcast to discuss market access excellence – what it means to him, and the critical role visual communication is playing for market access leaders.
Adrian also shares his views on what’s next for the market access function, detailing why leaders must embrace opportunities to demonstrate the value of market access and tell the story of their team’s success.
Strong communication strategies are clearly important to Adrian and it’s a theme that sits at the heart of this episode.
The opinions shared in this episode are Adrian's own views and not representative of the company he is working for. -
In this special episode, Louise teams up with colleagues Thomas Gilboy and Shravani Madishetti from Access Infinity to explore the transformative impact of digital on market access. Shravani, APAC Pricing and Market Access Lead, highlights the efficiency and accuracy achieved through digital tools while Tom, Product Owner for Nuro, emphasises the importance of maximising the effectiveness of digital tools. Together, they offer valuable insights and practical guidance for navigating this evolving landscape.
-
In the third episode of series 2, Louise interviews Khalid Mirza, Senior Director, Global Market Access & Pricing, Oncology at Daiichi Sankyo.
They discuss Khalid's journey into market access, and how, for him, it's evolved into an exciting career path where science meets commercial.
They also touch on the key themes shaping the future of market access, where Khalid's positive energy and passion for the function shines.
The opinions shared in this episode are Khalid's own views and not representative of the company he is working for. -
In this episode Louise teams up with Access Infinity Partner, Nick Proctor. Nick has been a consultant in the biopharmaceutical industry for over twenty years and shares his views on the hot topics and trends which he feels will have the biggest impact on market access in the coming years, also offering his insights on the themes which are 'hype'.
Throughout his career Nick has also been responsible for training, coaching and mentoring others in global market access and pricing, and talks to Louise about his passion for empowering aspiring market access leaders on their own professional growth journeys. -
Welcome back to the Market Access Matters podcast! In the first episode of series 2, Louise interviews David McConkey, Virology and Oncology Global Value and Access Director at Gilead Services.
Having started his career in consulting and then working across global and country roles, David has a breadth of experience in market access.
In this discussion he shares his experiences of taking on new challenges, leading teams into new territories and what he's learnt along the way.
The opinions shared in this episode are David's own views and not those of the company he is working for. -
In this episode we’re joined by Katie Gardner, who is Head of Global Market Access Excellence at Astellas. We hear Katie’s insights on the changing landscape of market access and what it demands from teams in terms of agility and innovation. She talks about how digital technology can empower teams to evolve with the ever-changing demands of the market and what her team are doing to drive market access excellence.
Katie is passionate about building high performing teams and discusses the role of mindset within this. It’s a fascinating discussion with valuable insights and advice shared, especially for market access professionals striving for professional growth.
The opinions shared in this podcast are Katie's own views. -
In this episode we're joined by Pfizer's Director Global Market Access for Medical Dermatology, Séverine Baquart. Séverine's career spans over twenty years at Pfizer, where she's seen significant change including the separation of the market access and pricing function from regulatory affairs. In this conversation, Séverine shares what she loves most about market access, the innovations she's seen and her aspirations for the future of market access on a global scale.
The opinions shared in this podcast are Séverine's own views. -
Shravani Madishetti is Access Infinity's APAC Pricing and Market Access Lead. Before taking on this role, Shravani specialised in pricing and market access for Novartis, where she was based for over seven years. She now leads a team that supports data functionality for our digital solutions, Access Hub and Nuro.
In this episode, we discuss Shravani's unique perspective on market access and why it provides a rewarding career path. -
In this episode we're joined by Paula Albuquerque, who is Director Global Market Access Immuno - Rheumatology at UCB. Paula has a comprehensive global background within the healthcare, pharmaceutical, biotech and management consulting sectors and has a strong focus on how to translate science into commercial value propositions.
Paula discusses her purpose: bringing to market and launching new medicines in the way that considers the needs and realities of the patients and health systems. She also reflects on key takeaways from the global launches she's been involved in, and shares what she's doing to prepare for the future of market access.
The opinions shared in this podcast are Paula's own views. -
In this episode, Louise interviews Access Infinity's Client Success Manager Cloë Carey. Cloë and her surrounding team are pioneering digital transformation in pharma and specifically, market access.
They discuss Cloë's natural interest in science when she was young and how this influenced her career path. Cloë also shares what it is about market access that keeps her engaged and excited as well as what she's learnt along the way. - Vis mere
